ViroPharma Looks To Enter HAE Market With Lev Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
Pennsylvania biotech assumes FDA will split HAE orphan designation, with Cinryze winning prophylaxis indication first.
You may also be interested in...
Cinryze Approved To Prevent HAE Attacks
Other candidates lined up for acute indication
Cinryze Approved To Prevent HAE Attacks
Other candidates lined up for acute indication
Latest Dyax Deal For DX-88 Should Bring In $10 Million
Massachusetts biotech licenses lead compound to Italy’s Dompe Farmaceutici for angioedema conditions.